fashion -WSS

fashion

author：knowledge 2025-08-24 09:38:13 - browse：97

UnitedHealth Group and Optum are getting rid of the name of their tech-driven care management company just months after the company faced congressional criticism over the use of its algorithms to cut off payments for patients’ care.

Discontinuing the NaviHealth name is part of a broader rebranding of Optum’s division that provides services to people at home and in post-acute facilities. The move also encapsulates how UnitedHealth is pushing to control every piece of patient care outside of the hospital and distancing itself from the aspects that have generated controversy.

Starting in the first quarter of 2024, Optum’s post-acute-care companies will be called Home & Community Care, according to internal documents obtained by STAT. However, Optum advised employees that “Home & Community Care should not be directly next to the Optum logo” in marketing materials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： FDA poised to publish guidelines for clinical trial diversity

hotspot

WSS

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Investigation reveals sickle cell patients pressured into sterilizations

Fentanyl is making it harder to start addiction treatment

Prime Medicine says its gene editing passes test in monkeys

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

focus

fashion

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

Questions and answers about ramping up H5N1 bird flu vaccine

Medicare details structure of new drug price negotiation program

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

Medicare details structure of new drug price negotiation program

Coloradans with cystic fibrosis could lose access to Trikafta

State Dept. review finds Biden bears some blame for Afghanistan failures

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

How one medical school became remarkably diverse

FDA poised to publish guidelines for clinical trial diversity

hotspot

Medicare must police algorithms in Medicare Advantage, Dems say

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Key Senate panel to consider PBM, drug pricing reform package

Life sciences investors close nearly $6 billion in new funds

What is microchimerism and how does it affect maternal health?

Inari Medical to buy amputation prevention company LimFlow

focus

hotspot

knowledge

Wikipedia